^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Excerpt:
...Patients must have histologically confirmed, BRAF-mutant (V600E/K) solid tumor...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

Published date:
05/13/2020
Excerpt:
HSP90 inhibition combined with BRAF/MEK inhibition was determined to be safe with evidence of disease control in a heavily pre-treated population of pts with BRAF V600E/K mut solid tumors.
DOI:
10.1200/JCO.2020.38.15_suppl.3609
Trial ID: